Arnott ID - Search Results

1

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW. Plevris N, et al. Among authors: arnott id. Dig Dis Sci. 2019 Jun;64(6):1660-1667. doi: 10.1007/s10620-018-5406-8. Epub 2018 Dec 7. Dig Dis Sci. 2019. PMID: 30535885

2

Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.

Arnott ID, Shand A, Ghosh S. Arnott ID, et al. Am J Gastroenterol. 2000 Nov;95(11):3326-7. doi: 10.1111/j.1572-0241.2000.03325.x. Am J Gastroenterol. 2000. PMID: 11095380 No abstract available.

3

Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease.

Arnott ID, Drummond HE, Ghosh S. Arnott ID, et al. Dig Dis Sci. 2001 Feb;46(2):402-9. doi: 10.1023/a:1005617302718. Dig Dis Sci. 2001. PMID: 11281191

4

Clinical use of Infliximab in Crohn's disease: the Edinburgh experience.

Arnott ID, McDonald D, Williams A, Ghosh S. Arnott ID, et al. Aliment Pharmacol Ther. 2001 Oct;15(10):1639-46. doi: 10.1046/j.1365-2036.2001.01092.x. Aliment Pharmacol Ther. 2001. PMID: 11564005 Clinical Trial.

5

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease.

Arnott ID, McNeill G, Satsangi J. Arnott ID, et al. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1451-7. doi: 10.1046/j.1365-2036.2003.01574.x. Aliment Pharmacol Ther. 2003. PMID: 12823146

6

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis.

Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. Ho GT, et al. Among authors: arnott id. Gastroenterology. 2005 Feb;128(2):288-96. doi: 10.1053/j.gastro.2004.11.019. Gastroenterology. 2005. PMID: 15685540

7

DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population.

Noble CL, Nimmo ER, Drummond H, Smith L, Arnott ID, Satsangi J. Noble CL, et al. Among authors: arnott id. Gut. 2005 Oct;54(10):1416-20. doi: 10.1136/gut.2005.066621. Epub 2005 Apr 20. Gut. 2005. PMID: 15843420 Free PMC article.

8

The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease.

Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID, Satsangi J. Noble CL, et al. Among authors: arnott id. Gastroenterology. 2005 Dec;129(6):1854-64. doi: 10.1053/j.gastro.2005.09.025. Gastroenterology. 2005. PMID: 16344054

9

Role of infliximab in ulcerative colitis: further questions.

Lees CW, Shand AG, Penman ID, Satsangi J, Arnott ID. Lees CW, et al. Among authors: arnott id. Inflamm Bowel Dis. 2006 Apr;12(4):335-7. doi: 10.1097/01.MIB.0000215095.69869.67. Inflamm Bowel Dis. 2006. PMID: 16633056 No abstract available.

10

Genetics of the innate immune response in inflammatory bowel disease.

Van Limbergen J, Russell RK, Nimmo ER, Ho GT, Arnott ID, Wilson DC, Satsangi J. Van Limbergen J, et al. Among authors: arnott id. Inflamm Bowel Dis. 2007 Mar;13(3):338-55. doi: 10.1002/ibd.20096. Inflamm Bowel Dis. 2007. PMID: 17206667 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters